Rhythm Pharmaceuticals, Inc.
IMCIVREE (setmelanotide)
acquired hypothalamic obesity
Resolved
110days ago
Approval decision · Mar 19, 2026
What's at stake
A final FDA approval decision on IMCIVREE (setmelanotide) for acquired hypothalamic obesity is expected Mar 19, 2026.
Primary source
· SEC 8-K
verified 15h ago
“Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the U.S. Food and Drug Administrat”